Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
Tag: Treatment strategies
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
